Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas

High glucose repatterns human podocyte energy metabolism during differentiation and diabetic nephropathy

(2017) Toshiyuki Imasawa et al.   FASEB JOURNAL

Recent advances of highly selective CDK4/6 inhibitors in breast cancer

(2017) Hanxiao Xu et al.   Journal of Hematology & Oncology

Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated WithCDK4Inhibitor Palbociclib

(2016) Mark A. Dickson et al.   JAMA Oncology

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

(2015) Nicholas C. Turner et al.   NEW ENGLAND JOURNAL OF MEDICINE

MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells

(2012) B. Wang et al.   ACTA BIOCHIMICA ET BIOPHYSICA SINICA

Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study

(2012) Isabelle Ray-Coquard et al.   LANCET ONCOLOGY

Advanced well-differentiated/dedifferentiated liposarcomas: role of chemotherapy and survival

(2011) A. Italiano et al.   ANNALS OF ONCOLOGY

Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis

(2011) Satoshi Watanabe et al.   BMC CANCER

Nutlin-3a Is a Potential Therapeutic for Ewing Sarcoma

(2010) K. I. Pishas et al.   CLINICAL CANCER RESEARCH

Clinical and Biological Significance of CDK4 Amplification in Well-Differentiated and Dedifferentiated Liposarcomas

(2009) A. Italiano et al.   CLINICAL CANCER RESEARCH

Nutlin-3 Affects Expression and Function of Retinoblastoma Protein

(2009) Wei Du et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Well-differentiated and dedifferentiated liposarcomas

(2009) Jean-Michel Coindre et al.   VIRCHOWS ARCHIV

The prognostic impact of dedifferentiation in retroperitoneal liposarcoma

(2008) Chiara Mussi et al.   CANCER

HMGA2 is the partner of MDM2 in well-differentiated and dedifferentiated liposarcomas whereas CDK4 belongs to a distinct inconsistent amplicon

(2008) Antoine Italiano et al.   INTERNATIONAL JOURNAL OF CANCER